scispace - formally typeset
M

M. A. Ghatei

Researcher at Imperial College London

Publications -  410
Citations -  37476

M. A. Ghatei is an academic researcher from Imperial College London. The author has contributed to research in topics: Enteroglucagon & Calcitonin gene-related peptide. The author has an hindex of 90, co-authored 410 publications receiving 36233 citations. Previous affiliations of M. A. Ghatei include Bristol Royal Infirmary & Hammersmith Hospital.

Papers
More filters

Hypothalamic actions of Neuromedin U

TL;DR: A novel role for NMU in the PVN is described to stimulate the hypothalamo-pituitary-adrenal axis and locomotor and grooming behavior and to inhibit feeding.
Journal ArticleDOI

Neuropeptide Y induced feeding in the rat is mediated by a novel receptor.

TL;DR: The novel fragment NPY(3–36) is as effective at stimulating food intake as the classical Y1 analogue [Pro34]-NPY but bound to the Y1 receptor with only 1/20th of the affinity of NPY and failed to inhibit adenylyl cyclase through this receptor.
Journal ArticleDOI

Leptin interacts with glucagon-like peptide-1 neurons to reduce food intake and body weight in rodents

TL;DR: ICV injection of the specific GLP‐1 receptor antagonist, exendin, at the onset of dark phase, did not affect feeding in saline pre‐treated controls, but blocked the reduction in food intake and body weight of leptin pre‐ treated rats, suggesting that GLp‐1 neurons are a potential target for leptin in its control of feeding.
Journal ArticleDOI

Ghrelin Has Partial or No Effect on Appetite, Growth Hormone, Prolactin, and Cortisol Release in Patients with Anorexia Nervosa

TL;DR: Ghrelin is unlikely to be effective as a single appetite stimulatory treatment for patients with AN, and the results suggest that AN patients are less sensitive to ghrelin in terms of GH response and appetite than healthy controls.
Journal ArticleDOI

Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus.

TL;DR: A significant improvement in postprandial glycaemic control with s/c GLP‐1 treatment that was fully maintained over a three‐week treatment period is demonstrated.